Prostate cancer
Conditions
Brief summary
Primary endpoint will be the efficacy of transdermal estradiol in mitigating the sexual symptoms of ADT
Detailed description
Occurrence of ADT-induced adverse effects during ADT in different study groups, Tolerability and safety of transdermal E2 during the one-year ADT adjuvant treatment period, Impact of transdermal E2 with or without 6-month resistance exercise on the muscle strength, functional capacity, body composition, lean-body muscle mass, and systematic biomarkers (g.e., blood biomarkers of and inflammatory health and muscle biomarkers), Safety and tolerability of 6-month physical exercise combined with or without transdermal E2 during ADT, Quality of life and perceived fatigue during ADT in different study groups
Interventions
DRUGEstrogel 0
DRUG6 mg/g -geeli
DRUGEstrogel® 0
DRUG6 mg/g-gel
DRUGdoseringspump
DRUGEnanton Depot Dual 11
DRUG25 mg injektiokuiva-aine ja liuotin suspensiota varten
DRUGesitäytetty ruisku
DRUGLEUPRORELIN
DRUGLeuprorelin Sandoz 5 mg implantaatti
Sponsors
Central Finland Hospital District Central Finland Hospital Nova
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint will be the efficacy of transdermal estradiol in mitigating the sexual symptoms of ADT | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of ADT-induced adverse effects during ADT in different study groups, Tolerability and safety of transdermal E2 during the one-year ADT adjuvant treatment period, Impact of transdermal E2 with or without 6-month resistance exercise on the muscle strength, functional capacity, body composition, lean-body muscle mass, and systematic biomarkers (g.e., blood biomarkers of and inflammatory health and muscle biomarkers), Safety and tolerability of 6-month physical exercise combined with or without transdermal E2 during ADT, Quality of life and perceived fatigue during ADT in different study groups | — |
Countries
Finland
Outcome results
None listed